Immunomodulation induced by interferon has been shown to reduce relapse rates after allogeneic BMT 7 and to induce graft-versus-host disease (GVHD). 8 There are A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell nonlimited data on the use of cytokines alone to treat relapse following allogeneic BMT. 3, 9 Shaffer et al 9 used the combidepleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse.
Summary:
Immunomodulation induced by interferon has been shown to reduce relapse rates after allogeneic BMT 7 and to induce graft-versus-host disease (GVHD). 8 There are A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell nonlimited data on the use of cytokines alone to treat relapse following allogeneic BMT. 3, 9 Shaffer et al 9 used the combidepleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse.
nation of interferon-␣ and interleukin-2 successfully to treat a patient with refractory acute myeloid leukemia (AML) Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due who relapsed less than 3 months after an allograft from an unrelated donor. Although the treatment was tolerated for to logistic difficulties in obtaining donor leukocytes, she was treated with interleukin-2 and interferon-␣2b.
only 2 weeks, acute GVHD developed and the leukemia went into remission. Long-term efficacy of the treatment Although the interleukin could be administered for a short period only, the interferon was continued for 4 could not be assessed as the patient died of fungal pneumonia a month later. In a previous report on adoptive months. Interferon was stopped when limited chronic graft-versus-host disease developed, but was followed by immunotherapy of relapsed AML after allogeneic BMT, 3 we have briefly mentioned the successful therapy of extramedullary and early marrow relapse. Reinstitution of interferon resulted in the development of sclerorelapsed secondary AML with interferon-␣2b and interleukin-2. In this report, we describe the complex course of derma-like extensive chronic GVHD and remission. Interferon was given for 5 months. GVHD improved events in this patient and provide current follow-up. slowly with treatment, but scleroderma-like changes still persist. The patient is alive with no evidence of disease and a Karnofsky score of 90% 41 months after Case report relapse and 26 months after stopping cyclosporine. We conclude that cytokines alone may occasionally result A 36-year-old woman of Greek origin was diagnosed to have acute myelomonocytic leukemia (CD13 + /CD34 + ) with in a durable response of acute leukemia relapsing after allografting, and should be considered in patients with no cytogenetic abnormality 15 months after successful therapy of metastatic choriocarcinoma with actinomycin D, a low tumor burden if it is difficult to obtain donor cells. Keywords: acute myeloid leukemia; graft-versus-host cyclophosphamide, etoposide, methotrexate and vincristine.
Complete remission was induced with idarubicin, high-dose disease; graft-versus-leukemia; immunotherapy; interferon, interleukin-2 cytarabine and etoposide. A first remission allograft was planned from an unrelated donor but, by the time she was actually transplanted 5 months after attaining remission, she was found to have relapsed in the marrow with normal Donor leukocyte infusions are increasingly being used in blood counts. the treatment of acute leukemia relapsing after allogeneic She underwent an uneventful allograft in first untreated blood or marrow transplantation.
1-5 The infused cells are relapse (15% blasts in the marrow) from an HLA A, B and often activated in vivo by administration of cytokines such DRB1 identical unrelated female donor who was misas interferon-␣ or interleukin-2 to enhance graft-versusmatched at one DQB1 locus (donor 0602, patient 0502). leukemia. [3] [4] [5] [6] The marrow was obtained through the National Marrow Donor Program (NMDP), and was not depleted of T cells. The conditioning regimen was 120 mg/kg cyclophospham-months post-transplant, when the peripheral blood counts were essentially normal. There was complete lymphoid chimerism with donor cells and DQB1 * 0502 was not detectable on PCR. Cyclosporine was discontinued immediately, but no GVHD developed over the following month and the marrow remained unchanged (12% blasts).
It was decided to use cytokines alone for immunotherapy because of logistic problems in obtaining donor leukocytes. She was commenced on 3 million units interferon-␣2b (Intron A; Schering-Plough, Welwyn Garden City, UK) subcutaneously every day and 18 million international units interleukin-2 (Proleukine; Chiron, Harefield, UK) subcutaneously three times a week. Interleukin-2 was tolerated poorly, and could be given irregularly for only 3 weeks due to fever, hypotension, cough, wheezing and lung infiltrates. ted flu-like symptoms responded to paracetamol. She remained on 3 million units of interferon three times small amount of residual or recurrent AML may show a weekly for 4 months initially, after which it was discongood response to cytokines, especially to interferon-␣. tinued due to systemic side-effects and development of de Although the initial immunotherapy which induced novo limited chronic cutaneous GVHD. Over this period of remission included the combination of interleukin-2 and time, the % blasts in the marrow fluctuated between 1 and interferon-␣, interleukin-2 could be tolerated for a short 6, and the blood counts and chemistry remained essentially while only, and maintenance therapy comprised interferonnormal except for striking large granular lymphocytosis, ␣ as a single agent. Also, after the second relapse (mainly eosinophilia, and some elevation of serum alkaline phosextramedullary), interferon was used as a single agent. phatase.
Interferon increases the expression of class I HLA antiShe developed a mass in the right elbow 2 months after gens and activates macrophages and lymphocytes. 10 This the withdrawal of interferon, which was clinically and may increase graft-versus-host reactivity and major historadiologically felt to be a thrombosed vascular lesion. Howcompatibility complex-restricted graft-versus-leukemia ever, it was found to be an extramedullary leukemic deposit reactions, and it may also facilitate cell-mediated anti-leuon excision biopsy. Bone marrow showed evidence of kemic reactions directly. 7 Interleukin-2 activates T cell-and residual disease with 4% blasts and interferon was restarted natural killer cell-based anti-tumor mechanisms, and has at the dose of 3 million units three times weekly. No local been found to be active in malignant hematologic diseases irradiation was administered to avoid interference with in the setting of autologous BMT and minimal residual dishealing of the surgical wound. Complete resolution of medease after chemotherapy.
11
ullary disease was achieved within a month and interferon Discontinuation of interferon and resolution of limited continued for a further 4 months. Interferon was stopped chronic GVHD which had lasted for 3 months was temwhen she developed chronic GVHD with severe scleroporally related to disease recurrence. However, the disease derma-like changes involving the skin of the upper limbs has not recurred a second time even though the patient has with high-titer nucleolar pattern antinuclear antibodies. The been off interferon for almost 2 years, probably because of changes spread to involve the lower limbs as well, and her extensive chronic GVHD. This suggests that chronic Karnofsky score declined from 100% to 70%. GVHD, at least for a certain length of time, may be essenShe received varying therapy for chronic GVHD as tial for sustained response. 3 shown in Figure 1 , with no obvious improvement in the The donor in this case, as in that described by Shaffer skin. However, over the last 7 months, she has shown gradet al, 9 was unrelated to the patient. The inherent histocomual, continuing improvement in the skin texture on intermitpatibility differences in this situation may have made tent methotrexate (15 mg weekly at the last follow-up).
response to cytokine therapy more likely than after sibling Results of serial marrow examinations are shown in transplants. 3 Because of this possibility and to avoid the Figure 1 . She has now been off interferon for 26 months, expense and inconvenience of a second donation in an unreand is alive in remission (December 1996) with normal lated donor setting, we propose to use cytokines alone when blood counts and a Karnofsky score of 90%. The eosinothe amount of disease is relatively small (10-15% blasts in philia resolved with cyclosporine-prednisolone, and the the marrow). 12 With more extensive disease, donor cells large granular lymphocytosis resolved approximately a year with or without preceding chemotherapy may still be the after stopping interferon. preferred approach.
